Evidence map›Paper›PMID 34846570›Full record

ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2022

Efficacy of dexamethasone in the management of malignant small bowel obstruction in advanced epithelial ovarian cancer.

Antonia P M Jones, Monica F G McGauran, Nisha Jagasia, Richard J Hiscock, Simon Hyde, Peter Grant

Abstract read
PubMed Publisher
In one paragraph

Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Observational
  2. Effects of anesthetics on development of gynecological cancer.Frontiers in cell and developmental biology · 2025
    Review
  3. Review
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Antonia P M JonesDepartment of Gynaecological Oncology, Mercy Hospital for Women, Heidelberg, VIC, 3078, Australia.
Monica F G McGauranDepartment of Gynaecological Oncology, Mercy Hospital for Women, Heidelberg, VIC, 3078, Australia. mmcgauran@mercy.com.au.
Nisha JagasiaDepartment of Gynaecological Oncology, Mater Hospital, South Brisbane, QLD, Australia.
Richard J HiscockTranslational Obstetrics Group, University of Melbourne, Heidelberg, VIC, Australia.
Simon HydeDepartment of Gynaecological Oncology, Mercy Hospital for Women, Heidelberg, VIC, 3078, Australia.
Peter GrantDepartment of Gynaecological Oncology, Mercy Hospital for Women, Heidelberg, VIC, 3078, Australia.
Mercy Hospital for Women · AUMater Adult Hospital · AURoyal Women's Hospital · AUUniversity of Melbourne · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionMalignant small bowel obstruction (MSBO) occurs in up to 50% of women with advanced epithelial ovarian cancer (EOC) causing symptom burden and distress to women and their families, particularly in the terminal stages of the disease. Corticosteroids are used to promote symptom resolution in malignant small bowel obstruction (MSBO) related to EOC, with little published data on their efficacy, optimal dosing and duration of treatment.

objectiveTo evaluate the efficacy of dexamethasone in achieving symptom control in women with advanced EOC presenting with MSBO, assess dexamethasone dosing and efficacy over subsequent presentations, and examine differences in dexamethasone responsiveness between platinum-resistant and platinum-sensitive patient.

methodsThis is a retrospective cohort study of women presenting with MSBO due to advanced EOC over a 12-year period from January 2005 to December 2016 in a single tertiary hospital.

resultsNinety-one women with MSBO were administered dexamethasone over 154 admissions with 89% of women initially achieving partial or complete symptom control. Dexamethasone responsiveness did not change with recurrent admissions, and platinum responsive patients were more likely to respond to dexamethasone than platinum-resistant patients (OR 3.6 [95%CI 1.1 to 12.2, p = 0.04]). A total of 15.6% of patients required additional measures to control symptoms of MSBO, and 44.8% had adequate symptom resolution to allow them to remain on or commence further treatment for EOC.

conclusionDexamethasone therapy is a useful adjunctive therapy in the management of symptoms associated with MSBO in women with EOC.

Indexed as

Neoplasms, Glandular and EpithelialOvarian NeoplasmsCarcinoma, Ovarian EpithelialDexamethasoneFemaleHumansNeoplasm Recurrence, LocalRetrospective StudiesDexamethasoneCarcinomaDexamethasoneIntestinal obstructionOvarian epithelialPalliative care

Identifiers

PMID34846570
OpenAlexW3189971315

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.